MX2022005450A - Composiciones que contienen cannabidiol (cbd) de accion periferica y usos de las mismas para mejorar la funcion sexual femenina o tratar trastornos sexuales femeninos. - Google Patents

Composiciones que contienen cannabidiol (cbd) de accion periferica y usos de las mismas para mejorar la funcion sexual femenina o tratar trastornos sexuales femeninos.

Info

Publication number
MX2022005450A
MX2022005450A MX2022005450A MX2022005450A MX2022005450A MX 2022005450 A MX2022005450 A MX 2022005450A MX 2022005450 A MX2022005450 A MX 2022005450A MX 2022005450 A MX2022005450 A MX 2022005450A MX 2022005450 A MX2022005450 A MX 2022005450A
Authority
MX
Mexico
Prior art keywords
female sexual
cbd
cannabidiol
containing compositions
peripherally acting
Prior art date
Application number
MX2022005450A
Other languages
English (en)
Inventor
Michael Frid
Harin Padma-Nathan
Original Assignee
Vella Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vella Bioscience Inc filed Critical Vella Bioscience Inc
Publication of MX2022005450A publication Critical patent/MX2022005450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
    • A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción provee composiciones que contienen cannabidiol (CBD) de acción periférica y métodos de uso de las mismas para tratar o mejorar la función sexual femenina. En algunas modalidades, las composiciones se proveen en forma de loción que contiene liposomas altamente cargados de CBD, que se aplica a los genitales femeninos poco antes de la actividad sexual.
MX2022005450A 2019-11-08 2020-11-03 Composiciones que contienen cannabidiol (cbd) de accion periferica y usos de las mismas para mejorar la funcion sexual femenina o tratar trastornos sexuales femeninos. MX2022005450A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932762P 2019-11-08 2019-11-08
US202062972288P 2020-02-10 2020-02-10
PCT/US2020/058722 WO2021091908A1 (en) 2019-11-08 2020-11-03 Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders

Publications (1)

Publication Number Publication Date
MX2022005450A true MX2022005450A (es) 2022-05-19

Family

ID=75848646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005450A MX2022005450A (es) 2019-11-08 2020-11-03 Composiciones que contienen cannabidiol (cbd) de accion periferica y usos de las mismas para mejorar la funcion sexual femenina o tratar trastornos sexuales femeninos.

Country Status (10)

Country Link
US (1) US20220401381A1 (es)
EP (1) EP4054335A4 (es)
JP (1) JP2023500372A (es)
KR (1) KR20220099991A (es)
CN (1) CN114901071A (es)
AU (1) AU2020377914A1 (es)
CA (1) CA3160634A1 (es)
IL (1) IL292775A (es)
MX (1) MX2022005450A (es)
WO (1) WO2021091908A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11717495B2 (en) * 2020-03-16 2023-08-08 Vella Bioscience, Inc. Use of cannabinoids in treating anti-depressant-induced female sexual dysfunction
US20230090691A1 (en) * 2021-09-01 2023-03-23 Spinart, LLC Compositions and methods for promoting and/or maintaining vaginovulval and perianal tissue vitality and tissue health
US20230321017A1 (en) * 2022-03-20 2023-10-12 Vella Bioscience, Inc. Acidic cannabinoids and uses thereof for enhancing female sexual function or treating female sexual disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228169A (en) 1979-06-26 1980-10-14 Pfizer Inc. 1,9-Dihydroxyoctahydrobenzo[c]quinolines and 1-hydroxyhexahydrobenzo[c]quinoline-9(8H)-ones as antiemetic agents
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
CA2483072A1 (en) 2002-04-25 2003-11-06 Virginia Commonwealth University Cannabinoids
WO2004017920A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
CA2526103A1 (en) 2003-05-20 2004-12-29 Bob M. Ii Moore Cannabinoid derivatives, methods of making, and use thereof
US7000812B2 (en) 2003-07-02 2006-02-21 Keith Gilstrap Bicycle wheel bag
US20060183922A1 (en) 2005-02-17 2006-08-17 Martin Billy R CB2-selective cannabinoid derivatives
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
JP2016537412A (ja) * 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． テルペン及びカンナビノイドの製剤
US10064905B1 (en) * 2013-11-11 2018-09-04 Ilysm, LLC Pharmaceutical preparation
US9655910B2 (en) * 2014-03-21 2017-05-23 Bodybio Inc. Compositions and methods for treating addiction
US20170246120A9 (en) * 2014-10-18 2017-08-31 Matthew J. Stepovich Herbal compositions including cannabidiol to enhance the sexual experience
WO2016098112A1 (en) * 2014-12-17 2016-06-23 One World Cannabis Ltd Novel condom comprising cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile dysfunction symptoms
BR112017018944A2 (pt) * 2015-03-02 2018-05-15 Afgin Pharma Llc método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)
WO2018156960A1 (en) * 2017-02-27 2018-08-30 Epstein Wendy Anne Compounds for treating cutaneous inflammation, female sexual disorders, and improving sexual function
US20180116998A1 (en) * 2015-05-13 2018-05-03 One World Cannabis Ltd Use of cannabis to treat fibromyalgia, methods and compositions thereof
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
CA3052146A1 (en) * 2017-02-01 2018-08-09 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
US20180360757A1 (en) * 2017-05-26 2018-12-20 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
CA2971197A1 (en) * 2017-06-20 2018-12-20 One World Cannabis Ltd Cannabis-based extracts and topical formulations for use in skin disorders
BR112020014253A2 (pt) * 2018-01-12 2020-12-08 Nutrae, LLC Formulações de canabinóides encapsuladas para administração oral
CA3049874C (en) * 2018-08-07 2021-05-25 Ilysm, LLC Compositions and methods for enhancing sexual pleasure and performance

Also Published As

Publication number Publication date
US20220401381A1 (en) 2022-12-22
JP2023500372A (ja) 2023-01-05
EP4054335A4 (en) 2023-09-27
WO2021091908A1 (en) 2021-05-14
CN114901071A (zh) 2022-08-12
KR20220099991A (ko) 2022-07-14
AU2020377914A1 (en) 2022-06-02
IL292775A (en) 2022-07-01
CA3160634A1 (en) 2021-05-14
EP4054335A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
MX2022005450A (es) Composiciones que contienen cannabidiol (cbd) de accion periferica y usos de las mismas para mejorar la funcion sexual femenina o tratar trastornos sexuales femeninos.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
ZA201701460B (en) Gamma-diketones for treatment and prevention of aging skin and wrinkles
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2022007376A (es) Fluoroalqull-oxadiazoles y sus usos.
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
MX2019011530A (es) Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2012013787A (es) Composiciones y metodos para estimular magp-1 y mejorar la apariencia de la piel.
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2022002686A (es) Cianopirrolidinas sustituidas con actividad como inhibidores de peptidasa 30 especifica de ubiquitina (usp30).
MX2018005796A (es) Reduccion de la sensacion de picazon en la piel.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2020008991A (es) Metodos para alterar la composicion corporal.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2017012598A (es) Composicion y proceso para moldear o modificar la forma del cabello.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
MX367321B (es) Composición para el cuidado de la piel y métodos para la misma.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
WO2021011875A8 (en) Compositions and methods for treating skin conditions